A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in pati-MedSci.cn

A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in pati

Galsky, MD; Necchi, A; Sridhar, SS; Ogawa, O; Ruscica, D; Angra, N; Bellmunt, J

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (7):

科室
- - 订阅+
  - 更多科室
工具
服务